{"id":1588,"date":"2025-07-23T16:28:48","date_gmt":"2025-07-23T16:28:48","guid":{"rendered":"https:\/\/enfoca.com.mx\/?p=1588"},"modified":"2026-10-07T17:49:59","modified_gmt":"2026-10-07T17:49:59","slug":"tratamientos-anti-vegf-retina","status":"publish","type":"post","link":"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/","title":{"rendered":"Anti-VEGF Therapies in Retina: Advances and Challenges | Samur A-I"},"content":{"rendered":"<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"SamurA-I #8 Anti VEGF UPDATE\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/Q5Vz180Whf4?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Advances and Challenges in Anti-VEGF Therapies for Retinal Diseases<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Advances and Challenges in Anti-VEGF Therapies for Retinal Diseases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph translation-block\"><strong>Anti-VEGF therapies<\/strong> have transformed the treatment of <strong>retinal diseases<\/strong> such as <strong>neovascular (wet) macular degeneration<\/strong>, <strong>diabetic macular edema<\/strong>, and <strong>retinal vein occlusions<\/strong>. However, <strong>injection frequency<\/strong> and <strong>treatment burden for the patient<\/strong> remain key challenges. The main goal is to preserve vision while minimizing the impact on the patient's life.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Anti-VEGF Treatment Strategies: Balancing Efficacy and Convenience<\/h3>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">There are three main approaches to administering <strong>anti-VEGF therapies<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"translation-block\"><strong>Fixed Dosing (FIDO):<\/strong> Delivers <strong>strong visual outcomes<\/strong> but involves a <strong>high treatment burden<\/strong> with very frequent injections (about 11 per year), which significantly affects the patient's time and costs.<\/li>\n\n\n\n<li class=\"translation-block\"><strong>As Needed (PRN &#8211; Pro Re Nata):<\/strong> Reduces the number of injections (4 to 8 per year), but carries the risk of undertreatment and possible <strong>long-term vision loss<\/strong> if the disease reactivates between visits.<\/li>\n\n\n\n<li class=\"translation-block\"><strong>Treat-and-Extend (TNE &#8211; Treat and Extend):<\/strong> Considered the <strong>preferred<\/strong> regimen by many specialists, TNE seeks a balance between <strong>visual efficacy<\/strong> and a <strong>lower treatment burden<\/strong>. It starts with frequent injections and, if the eye remains stable, the intervals are gradually extended. This makes it possible to maintain visual outcomes similar to fixed dosing with fewer injections (8 to 10 per year on average).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Anti-VEGF Drugs and Future Innovations<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Anti-VEGF Drugs and Future Innovations<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"translation-block\"><strong>Current drugs:<\/strong> <strong>Aflibercept (Aflivers)<\/strong> and <strong>Ranibizumab (Ran Bisumab)<\/strong> are effective in the TNE regimen, allowing longer intervals. <strong>Bevacizumab (Bebas Isumap)<\/strong> is a more affordable option used \"off label,\" with debate over possible systemic risks.<\/li>\n\n\n\n<li class=\"translation-block\"><strong>New drugs:<\/strong> <strong>Brolucizumab (Brulusumap)<\/strong> promised longer intervals, but raised concerns about intraocular inflammation. <strong>Faricimab (Farisim)<\/strong> is a promising development that targets two pathways and aims to extend intervals up to 16 weeks. Higher doses of existing drugs and the arrival of <strong>biosimilars<\/strong>, which could lower costs, are also being explored.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">The Burden of Treatment and Patient Adherence<\/h3>\n\n\n\n<p class=\"wp-block-paragraph translation-block\"><strong>Treatment burden<\/strong> goes beyond the injection itself and includes time, logistics, emotional aspects, and dependence. This burden is a key factor in patients' <strong>poor adherence<\/strong>, explaining the <strong>gap between clinical trial results and everyday practice<\/strong>. Optimal adherence is vital to maintaining vision gains over the long term.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The Future: Fewer Injections, Greater Impact<\/h3>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Research is focused on <strong>reducing treatment frequency<\/strong> without compromising efficacy. The main avenues include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"translation-block\"><strong>Long-acting drugs:<\/strong> Such as Faricimab, aiming for intervals of three or four months.<\/li>\n\n\n\n<li class=\"translation-block\"><strong>Sustained-release implantable devices:<\/strong> Small reservoirs that release medication continuously for months (e.g., <strong>Sus Bimo<\/strong>), drastically reducing the need for injections, although they require initial surgery.<\/li>\n\n\n\n<li class=\"translation-block\"><strong>Gene therapy:<\/strong> A transformative approach that aims to have the eye produce the anti-VEGF protein continuously, with the potential for a one-time treatment that lasts for years.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">In conclusion, the choice of anti-VEGF strategy should be individualized, aiming to <strong>maximize vision and minimize treatment burden<\/strong>. The field is advancing rapidly toward less frequent options, which will improve patient adherence and quality of life.<\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Interested in going deeper into <strong>ophthalmology<\/strong>? Discover more <strong>summaries of key topics<\/strong> and <strong>AI-guided reviews<\/strong> to stay up to date with the <strong>latest advances<\/strong>. Click here!: <a href=\"https:\/\/enfoca.com.mx\/eng\/podcast-samur-ai\/\">https:\/\/enfoca.com.mx\/podcast-samur-ai\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">If you prefer more dynamic content, explore our <strong>exclusive interviews<\/strong> and <strong>live case analyses<\/strong>, click here!: <a href=\"https:\/\/enfoca.com.mx\/eng\/podcast-samureye\/\">https:\/\/enfoca.com.mx\/podcast-samureye\/<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph translation-block\">Don't miss any updates: Follow us on <strong><a href=\"https:\/\/www.instagram.com\/samureyepodcast\/\">Instagram<\/a><\/strong> and <strong><a href=\"https:\/\/www.youtube.com\/channel\/UCMiaTjc7s672UjW4msyA09g\">YouTube<\/a><\/strong> for daily content on <strong>eye health<\/strong> and <strong>eye diseases<\/strong>!<br><br><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>","protected":false},"excerpt":{"rendered":"<p>Avances y Desaf\u00edos en Terapias Anti-VEGF para Enfermedades Retinianas Avances y Desaf\u00edos en Terapias Anti-VEGF para Enfermedades Retinianas Las terapias [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":1589,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[9,10],"tags":[137,131,136,139,143,130,128,142,138,141,140,133,14,134,129,20,68,135,132],"class_list":["post-1588","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-podcast","category-samur-a-i","tag-aflibercept","tag-anti-vegf","tag-bevacizumab","tag-brolucizumab","tag-carga-del-paciente","tag-degeneracion-macular","tag-edema-macular-diabetico","tag-enfermedades-de-la-vista","tag-faricimab","tag-implantes-de-liberacion-sostenida","tag-inyecciones-oculares","tag-oclusiones-de-la-vena-retiniana","tag-oftalmologia","tag-ranibizumab","tag-retina","tag-salud-ocular","tag-terapia-genica","tag-tne","tag-treat-and-extend"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Terapias anti-VEGF en retina: avances y retos | Samur A-I<\/title>\n<meta name=\"description\" content=\"Samur A-I: tratamientos anti-VEGF para degeneraci\u00f3n macular y otras enfermedades de retina, esquemas de tratar y extender y nuevos f\u00e1rmacos.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Terapias anti-VEGF en retina: avances y retos | Samur A-I\" \/>\n<meta property=\"og:description\" content=\"Samur A-I: tratamientos anti-VEGF para degeneraci\u00f3n macular y otras enfermedades de retina, esquemas de tratar y extender y nuevos f\u00e1rmacos.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/\" \/>\n<meta property=\"og:site_name\" content=\"ENFOCA\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-23T16:28:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-07T17:49:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Riquelme\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Riquelme\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\"},\"author\":{\"name\":\"Riquelme\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#\\\/schema\\\/person\\\/6a00856a1ddde6dfe3a27187c99d0dad\"},\"headline\":\"Terapias anti-VEGF en retina: avances y retos | Samur A-I\",\"datePublished\":\"2025-07-23T16:28:48+00:00\",\"dateModified\":\"2026-10-07T17:49:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\"},\"wordCount\":685,\"image\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/ANTI-VEGF.png\",\"keywords\":[\"Aflibercept\",\"anti-VEGF\",\"Bevacizumab\",\"Brolucizumab\",\"carga del paciente\",\"degeneraci\u00f3n macular\",\"edema macular diab\u00e9tico\",\"enfermedades de la vista\",\"Faricimab\",\"implantes de liberaci\u00f3n sostenida\",\"inyecciones oculares\",\"oclusiones de la vena retiniana\",\"Oftalmolog\u00eda\",\"Ranibizumab\",\"retina\",\"Salud ocular\",\"Terapia G\u00e9nica\",\"TNE\",\"Treat-and-Extend\"],\"articleSection\":[\"Podcast\",\"Samur A-I\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\",\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\",\"name\":\"Terapias anti-VEGF en retina: avances y retos | Samur A-I\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/ANTI-VEGF.png\",\"datePublished\":\"2025-07-23T16:28:48+00:00\",\"dateModified\":\"2026-10-07T17:49:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#\\\/schema\\\/person\\\/6a00856a1ddde6dfe3a27187c99d0dad\"},\"description\":\"Samur A-I: tratamientos anti-VEGF para degeneraci\u00f3n macular y otras enfermedades de retina, esquemas de tratar y extender y nuevos f\u00e1rmacos.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#primaryimage\",\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/ANTI-VEGF.png\",\"contentUrl\":\"https:\\\/\\\/enfoca.com.mx\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/ANTI-VEGF.png\",\"width\":1920,\"height\":1080,\"caption\":\"Anti VEGF\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/tratamientos-anti-vegf-retina\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/enfoca.com.mx\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Terapias anti-VEGF en retina: avances y retos | Samur A-I\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#website\",\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/\",\"name\":\"ENFOCA\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/enfoca.com.mx\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/enfoca.com.mx\\\/#\\\/schema\\\/person\\\/6a00856a1ddde6dfe3a27187c99d0dad\",\"name\":\"Riquelme\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g\",\"caption\":\"Riquelme\"},\"url\":\"https:\\\/\\\/enfoca.com.mx\\\/eng\\\/author\\\/drriquelme\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anti-VEGF Therapies in Retina: Advances and Challenges | Samur A-I","description":"Samur A-I: tratamientos anti-VEGF para degeneraci\u00f3n macular y otras enfermedades de retina, esquemas de tratar y extender y nuevos f\u00e1rmacos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/","og_locale":"en_US","og_type":"article","og_title":"Terapias anti-VEGF en retina: avances y retos | Samur A-I","og_description":"Samur A-I: tratamientos anti-VEGF para degeneraci\u00f3n macular y otras enfermedades de retina, esquemas de tratar y extender y nuevos f\u00e1rmacos.","og_url":"https:\/\/enfoca.com.mx\/eng\/tratamientos-anti-vegf-retina\/","og_site_name":"ENFOCA","article_published_time":"2025-07-23T16:28:48+00:00","article_modified_time":"2026-10-07T17:49:59+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","type":"image\/png"}],"author":"Riquelme","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Riquelme","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#article","isPartOf":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/"},"author":{"name":"Riquelme","@id":"https:\/\/enfoca.com.mx\/#\/schema\/person\/6a00856a1ddde6dfe3a27187c99d0dad"},"headline":"Terapias anti-VEGF en retina: avances y retos | Samur A-I","datePublished":"2025-07-23T16:28:48+00:00","dateModified":"2026-10-07T17:49:59+00:00","mainEntityOfPage":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/"},"wordCount":685,"image":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#primaryimage"},"thumbnailUrl":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","keywords":["Aflibercept","anti-VEGF","Bevacizumab","Brolucizumab","carga del paciente","degeneraci\u00f3n macular","edema macular diab\u00e9tico","enfermedades de la vista","Faricimab","implantes de liberaci\u00f3n sostenida","inyecciones oculares","oclusiones de la vena retiniana","Oftalmolog\u00eda","Ranibizumab","retina","Salud ocular","Terapia G\u00e9nica","TNE","Treat-and-Extend"],"articleSection":["Podcast","Samur A-I"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/","url":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/","name":"Anti-VEGF Therapies in Retina: Advances and Challenges | Samur A-I","isPartOf":{"@id":"https:\/\/enfoca.com.mx\/#website"},"primaryImageOfPage":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#primaryimage"},"image":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#primaryimage"},"thumbnailUrl":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","datePublished":"2025-07-23T16:28:48+00:00","dateModified":"2026-10-07T17:49:59+00:00","author":{"@id":"https:\/\/enfoca.com.mx\/#\/schema\/person\/6a00856a1ddde6dfe3a27187c99d0dad"},"description":"Samur A-I: tratamientos anti-VEGF para degeneraci\u00f3n macular y otras enfermedades de retina, esquemas de tratar y extender y nuevos f\u00e1rmacos.","breadcrumb":{"@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#primaryimage","url":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","contentUrl":"https:\/\/enfoca.com.mx\/wp-content\/uploads\/2025\/07\/ANTI-VEGF.png","width":1920,"height":1080,"caption":"Anti VEGF"},{"@type":"BreadcrumbList","@id":"https:\/\/enfoca.com.mx\/tratamientos-anti-vegf-retina\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/enfoca.com.mx\/"},{"@type":"ListItem","position":2,"name":"Terapias anti-VEGF en retina: avances y retos | Samur A-I"}]},{"@type":"WebSite","@id":"https:\/\/enfoca.com.mx\/#website","url":"https:\/\/enfoca.com.mx\/","name":"ENFOCA","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/enfoca.com.mx\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/enfoca.com.mx\/#\/schema\/person\/6a00856a1ddde6dfe3a27187c99d0dad","name":"Riquelme","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3b9384ad7fa2d6e84d48469ed47a8f59d5aabb450520c89d601926a2d82ad8da?s=96&d=mm&r=g","caption":"Riquelme"},"url":"https:\/\/enfoca.com.mx\/eng\/author\/drriquelme\/"}]}},"_links":{"self":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts\/1588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/comments?post=1588"}],"version-history":[{"count":3,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts\/1588\/revisions"}],"predecessor-version":[{"id":3966,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/posts\/1588\/revisions\/3966"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/media\/1589"}],"wp:attachment":[{"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/media?parent=1588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/categories?post=1588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/enfoca.com.mx\/eng\/wp-json\/wp\/v2\/tags?post=1588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}